Sonoma Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2018: 0.00%

Sonoma Pharmaceuticals Inc (SNOA) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$14.35 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2018)

This chart shows how Sonoma Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check Sonoma Pharmaceuticals Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Sonoma Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SNOA market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Sonoma Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Sonoma Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Sonoma Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 48.48%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 11.69%
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
Drug Manufacturers - Specialty & Generic 4.31%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 15.57%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
Drug Manufacturers - Specialty & Generic 18.70%

Annual Asset Resilience Ratio for Sonoma Pharmaceuticals Inc (2007–2018)

The table below shows the annual Asset Resilience Ratio data for Sonoma Pharmaceuticals Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2018-03-31 0.00% $0.00 $19.21 Million --
2017-03-31 0.00% $0.00 $25.46 Million --
2016-03-31 0.00% $0.00 $13.80 Million --
2015-03-31 0.00% $0.00 $15.05 Million --
2014-03-31 0.00% $0.00 $20.79 Million --
2013-03-31 0.00% $0.00 $12.56 Million --
2012-03-31 0.00% $0.00 $7.84 Million --
2007-03-31 7.42% $2.00 Million $26.95 Million --
pp = percentage points

About Sonoma Pharmaceuticals Inc

NASDAQ:SNOA USA Drug Manufacturers - Specialty & Generic
Market Cap
$3.82 Million
Market Cap Rank
#29031 Global
#5867 in USA
Share Price
$1.10
Change (1 day)
-2.65%
52-Week Range
$1.01 - $5.35
All Time High
$1425.42
About

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more